Arrowstreet Capital’s Immunogen Inc IMGN Stock Holding History

Arrowstreet Capital’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-679,401	Closed	-$3.13M	–	2578
2020 Q2	$3.13M	Buy	679,401 +61,712	+10%	+$262K	0.01%	1262
2020 Q1	$2.11M	Buy	617,689 +374,539	+154%	+$1.64M	0.01%	1044
2019 Q4	$1.24M	Buy	+243,150	New	+$825K	﹤0.01%	1284
2018 Q2	–	Sell	-690,445	Closed	-$7.26M	–	1347
2018 Q1	$7.26M	Buy	690,445 +428,503	+164%	+$4.23M	0.02%	501
2017 Q4	$1.68M	Sell	261,942 -555,674	-68%	-$3.43M	﹤0.01%	862
2017 Q3	$6.25M	Buy	817,616 +803,216	+5,578%	+$5.34M	0.02%	462
2017 Q2	$102K	Buy	+14,400	New	+$65.9K	﹤0.01%	1024
2013 Q4	–	Sell	-61,589	Closed	-$1.05M	–	1318
2013 Q3	$1.05M	Buy	+61,589	New	+$1.08M	0.01%	664

Other funds holding IMGN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's IMGN Position: Q3 2020 in Review

Arrowstreet Capital sold out of Immunogen Inc (IMGN) in Q3 2020, closing a stake of 679,401 shares — an estimated $3.13M sold.

Arrowstreet Capital first reported a position in IMGN in Q3 2013 and held it in 8 quarters. The position peaked at $7.26M in Q1 2018. 185 funds tracked by Wall St. Rank hold IMGN as of Q3 2020.

Arrowstreet Capital reported no remaining Immunogen Inc position as of Q3 2020 after selling out during the quarter.
Arrowstreet Capital sold 679,401 Immunogen Inc shares in Q3 2020, an estimated $3.13M.
Arrowstreet Capital first reported a position in Immunogen Inc in Q3 2013 and held it in 8 quarters.
Arrowstreet Capital's Immunogen Inc position peaked at $7.26M in Q1 2018.
185 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2020.

Based on Arrowstreet Capital's 13F filing for Q3 2020, filed 12 Nov 2020.